DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Indatuximab ravtansine
Indatuximab ravtansine
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
ADC (Antibody-Drug Conjugates
Monoclonal Antibodies in Myeloma
Immunotherapies Shape the Treatment Landscape for Hematologic Malignancies Jane De Lartigue, Phd
Novel Targets in Multiple Myeloma
Immunotherapy in Multiple Myeloma
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Antibody-Drug Conjugates: Possibilities and Challenges
Antibody–Drug Conjugates for Cancer Therapy
INN Working Document 05.179 Update 2011
IMSN Letter on Antibody-Drug Conjugates 2015 03 23
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
Sundar Jagannath, MD
(INN) for Biological and Biotechnological Substances
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Indatuximab Ravtansine) • BT062 (0.5 Mg/Kg, 1 Mg/Kg, 2 Mg/Kg, Or 4 Mg/Kg) Administered Intravenously Once Weekly (Total 6 Injections)
Top View
Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma Bo Yu1 and Delong Liu2,3*
Advances in the Management of Myeloma
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Antibody Drug Conjugates (ADC)
Therapeutic Outcome of Early-Phase Clinical Trials in Multiple Myeloma: a Meta-Analysis Niels Van Nieuwenhuijzen1,2,Rowanfrunt 1, Anne M
Methods and Compositions for Prediction of Therapeutic Efficacy of Cancer Treatments and Cancer Prognosis Upon Antibody Treatment
Monoclonal Antibodies in the Treatment of Multiple Myeloma: Current Status and Future Perspectives
Global Antibody-Drug Conjugate (ADC) Clinical Trial Review Global Antibody-Drug Conjugate (ADC)
Prescrire's Contribution to the WHO Consultation on List 112 Of
Safety of Medicines
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
VIS832, a Novel CD138-Targeting Monoclonal Antibody, Potently
IMSN Open Letter on Antibody-Drug Conjugate 2151012
Indatuximab Ravtansine (BT062)
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
Novel Targets in Multiple Myeloma
Ep 3088005 A1
(19) United States Mar. 12, 2015
Oncology Drugs in the Pipeline
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Monoclonal Antibodies for the Treatment of Multiple Myeloma: an Update